jain.com

Penny Warrants issuance to lenders

Company: TeraWulf

This claim was marked delayed on September 14, 2026. Recorded automatically from the cited source when it was published, then queued for evidence review.

How this was decided: Automated extraction from the cited source. The claim is preserved below exactly as it was originally published, so the record shows what was asserted as well as what became of it.

Subject kind
financing
Statement date
2023-03-02
Promised by
2024-04-01
Promised amount
26666669.0 shares
Current status
delayed

The claim, verbatim

Company issued 26,666,669 Penny Warrants to lenders representing 10% of fully diluted equity with exercise price of $0.01 per share, exercisable from April 1, 2024 through December 31, 2025

Source (primary)

TeraWulf 8-K filed 2023-03-03 (SEC EDGAR, sec_filing)
View cached copy (2026-09-13)Live source ↗

Quote: “26,666,669 warrants to purchase an aggregate number of shares of the Company's common stock equal to 10.0% of the fully diluted equity of the Company as of the Fifth Amendment Effective Date with an exercise price of $0.01 per share”

How we checked this

This claim has not yet been checked assertion-by-assertion against its source. It carries a cited source and quote, but the deeper check has not run. When it does, the result appears here whatever it says.

Additional evidence

confirms TeraWulf 8-K filed 2023-03-03

Quote: “26,666,669 warrants to purchase an aggregate number of shares of the Company's common stock equal to 10.0% of the fully diluted equity of the Company as of the Fifth Amendment Effective Date with an exercise price of $0.01 per share”

View cached copy (2026-09-13)Live source ↗

Record of changes

September 13, 2026 — stated
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.
September 14, 2026 — delayed
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.